

Active Protocols

Note: Click on the protocol title to view the eligibility requirements.

Type of Cancer Breast

Protocol Title

[NSABP B-55/](#)
BIG 6-13

Protocol Name

A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study To Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients With Germline BRCA 1 and 2 Mutations And High Risk HER-2 Negative Primary Breast Cancer who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy

Sponsor

NRG Oncology

Munster Investigator

Robin, Fuller, Kassar
Shah, Tothy, Bose

[NSABP B-52](#)

A Randomized Phase III Trial Evaluating Pathologic Complete Response Rates in Patients with Hormone Receptor-Positive, HER2-Positive, Large Operable and Locally Advanced Breast Cancer Treated with Neoadjuvant Therapy of Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab (TCHP) With or Without Estrogen Deprivation

NRG Oncology

Robin, Fuller, Kassar
Shah, Tothy, Bose

[BRE12-158](#)

A Phase II Randomized Controlled Trial Of Genomically Directed Therapy in Patients with Triple Negative Breast Cancer

Hoosier Cancer

Robin, Fuller, Kassar,
Shah, Tothy, Bose

[SWOG 1207](#)

Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One year of Everolimus In Patients with High-Risk, Hormone Receptor Positive and HER2/neu Negative Breast Cancer

CTSU

Robin, Fuller, Wallace,
Shah, Kassar,
Tothy, Bose

[PUMA NER 1301](#)

A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2-Directed Regimens in the Metastatic Setting (NALA)

PUMA

Robin, Fuller, Wallace
Shah, Kassar

Type of Cancer Colon

Protocol Title

[CALGB/SWOG C80702](#)

Protocol Name

A Phase III Trial of Adjuvant FOLFOX Plus Celecoxib or Placebo For Patients with Resected Stage III Colon Cancer

Sponsor

CTSU

Munster Investigator

Robin, Fuller, Wallace,
Shah, Kassar

Type of Cancer Renal

Protocol Title

[SWOG S0931](#)

[A031201](#)

Protocol Name

VEErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma

Phase III Trial of Enzalutamide (NSCC#755085) Versus Enzalutamide, Abiraterone and Prednisone For Castration Resistant Metastatic Prostate Cancer

Sponsor

GOG

Alliance

Munster Investigator

Kassar, Shah, Robin
Fuller, Tothy, Bose

Kassar, Shah, Robin
Fuller, Tothy, Bose

Type of Cancer Colon (Observational)

Protocol Title

[OBS13579/OZONE](#)

Protocol Name

Prospective international observational cohort non-comparative study describing the safety and effectiveness of ZALTRAP® administered in combination with FOLFIRI for the treatment of patients with metastatic colorectal cancer in current clinical practice: A Post-Authorisation Safety Study (PASS)

Sponsor

Sanofi Aventis

Munster Investigator

Robin, Fuller, Wallace
Shah, Kassar

Type of Cancer Endometrial

Protocol Title

[Connect MM](#)

Protocol Name

The Multiple Myeloma Disease Registry resected Colon Cancer

Sponsor

Celgene

Munster Investigator

Robin, Fuller, Kozloff
Shah, Kassar, Wallace

Type of Cancer Lung (Adjuvant)

Protocol Title

[A081105](#)

Protocol Name

Randomized Double Blind Placebo-Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)

Sponsor

CTSU

Munster Investigator

Robin, Fuller, Kassar, Shah
Tothy, Bose, Sloan

[A151216](#)
(ALCHEMIST)

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial

CTSU

Robin, Fuller, Kassar, Shah
Tothy, Bose, Sloan

[ECOG E4512](#)

A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

CTSU

Robin, Fuller, Kassar, Shah
Tothy, Bose, Sloan

Type of Cancer Lung (Metastatic Squamous)

Protocol Title

[S1400](#)

Protocol Name

Phase II/III Biomarker-Driven Master Protocol For Second Line Therapy of Squamous Cell Lung Cancer

Sponsor

CTSU

Munster Investigator

Robin, Fuller, Kassir, Shah Tohy, Bose, Sloan

[S1400A](#)

A Phase II/III Randomized Study of MEDI4736 Versus Chemotherapy as Second Line Therapy For Patients with Squamous Cell Lung Cancer And No Matching Biomarkers

CTSU

Robin, Fuller, Kassir, Shah Tohy, Bose, Sloan

[S1400B](#)

A Phase II/III Randomized Study of GDC-0032 Versus Chemotherapy as Second Line Therapy For Biomarker Selected Patients with Squamous Cell Lung Cancer

CTSU

Robin, Fuller, Kassir, Shah Tohy, Bose, Sloan

[S1400C](#)

A Phase II/III Randomized Study of Palbociclib Versus Chemotherapy as Second Line Therapy For Biomarker Selected Patients with Squamous Cell Lung Cancer

CTSU

Robin, Fuller, Kassir, Shah Tohy, Bose, Sloan

[S1400D](#)

A Phase II/III Randomized Study of AZD4547 Versus Chemotherapy As Second Line Therapy For Biomarker Selected Patients with Squamous Cell Lung Cancer

CTSU

Robin, Fuller, Kassir, Shah Tohy, Bose, Sloan

Type of Cancer Ovarian

Protocol Title

[CTSU GOG 0213](#)

Protocol Name

A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel Alone or in Combination with Bevacizumab (NSC #704865, IND #7921) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal primary and Fallopian Tube Cancer

Sponsor

CTSU

Munster Investigator

Robin, Fuller, Kozloff Wallace, Shah, Kassir